Role of epithelial mesenchymal transition (EMT) in chronic obstructive pulmonary disease (COPD)

Sukhwinder Singh Sohal1 and Eugene Haydn Walters1,2*

Abstract
Small airway fibrosis is the main contributor to physiological airway dysfunction in COPD. One potential mechanism contributing to small airway fibrosis is epithelial mesenchymal transition (EMT). When associated with angiogenesis (so called EMT-Type-3) it may well also be the link with the development of cancer, which is closely associated with COPD and predominantly in large airways. In a recent study published in Respiratory Research, Qin Wang and colleagues investigated the role of urokinase plasminogen activator receptor (uPAR) in EMT in small airway epithelium of COPD patients. However, there are some issues with the paper which we wish to comment on.

Keywords: Epithelial mesenchymal transition, Small airways, Large airways, COPD, Lung cancer, Vimentin

Letter to the Editor
Dear Editor
We read with interest the recent paper by Qin Wang and colleagues published in Respiratory Research (2013, 14:67, doi:10.1186/1465-9921-14-67), addressing epithelial mesenchymal transition (EMT) in COPD airways [1]. This is an important new area and it is quite reassuring that leading respiratory journals are now recognising the potential importance of EMT in pathogenesis of chronic obstructive pulmonary disease (COPD) and its deadly consequences. In this paper the authors conclude that increased urokinase plasminogen activator receptor (uPAR) expression in the small airway epithelium of patients with COPD is a manifestation of an active EMT process [1]. However, we have some issues with the paper.

Firstly, in the discussion Qin Wang and et al. questioned the relevance of our findings on active EMT in large airways of COPD patients. We agree that EMT-type-2 may be involved in pathogenesis of small airway and obliteration. However, a second major feature of COPD, namely, the striking vulnerability of early stage COPD to development of lung cancer [2-4], is also poorly understood. We have suggested that EMT-type-3 in larger airways provides an explanation [2-9]. Wang and et al. have missed this point in our paper, by being overly focused on EMT in small airways, EMT also seems to feature in idiopathic pulmonary fibrosis (IPF) and bronchiolitis obliterans syndrome (BOS) [2-11].

EMT when associated with increased angiogenesis of the reticular basement membrane (Rbm) and indeed epithelium itself (Figure 1), leads to the formation of a pro-cancer stroma (EMT-type-3) in contrast to mainly fibrosis-associated EMT-type-2 which lacks angiogenesis [2-4,7-9,12]. It is thought that this aberrant vessel plexus gives immune protection to developing malignant cells by preventing egress and local activity of natural killer (NK) cells [13,14]. Fibroblasts originated from type-3 EMT are designated as “cancer-associated fibroblasts” [15]. This is well described in other epithelial malignancies [16]. It is of interest and relevance in this context that over 90% of human cancer arises in epithelia (e.g. breast, colon, stomach, liver, prostate, ovary/fallopian tube, bladder etc.), and the involvement of EMT in all of these may be a central paradigm [16]. It is pertinent that up to 70% of lung cancer occurs in the context of mild-to-moderate COPD [17-19], and COPD-related cancer may well be just another example of this core principle of unstable epithelium in the context of tissue inflammation and/or chronic stimulation.

* Correspondence: haydn.walters@utas.edu.au
1 NHMRC Centre of Research Excellence for Chronic Respiratory Disease, School of Medicine, University of Tasmania, Hobart 7000, Australia
2 NHMRC Centre for Research Excellence in Chronic Respiratory Disease, School of Medicine, University of Tasmania, MS1, 17 Liverpool Street, Private Bag 23, Hobart, Tasmania 7000, Australia

© 2013 Sohal and Walters; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Our second major issue is the quality of immunostaining of small airway sections for EMT bio-markers in the Wang paper. In Figure 1A, the serial sections from COPD patients stained for E-cadherin (b) and vimentin (d) are not convincing. There is indeed decreased expression of E-cadherin in the epithelium but the authors failed to point out what other cells are staining for E-cadherin nearly 150 microns deep in the lamina propria (LP). If they have migrated from the epithelium they should have lost E-cadherin and should be positive for vimentin in the LP. This suggests some artefact; perhaps the authors should have considered double immunostaining for these markers. In addition, the non-smoker small airway tissue section demonstrates a quite hyperplastic appearance of the epithelium, suggesting aberrant phenotyping.

Finally, the authors show correlations between the expression of cell mesenchymal markers in small airways and lung function for all the 78 subjects together. However, this includes quite distinct groups, including normal, which are bound to give such a relationship. What is needed is an analysis of obstructed participants only, to see if greater expression of markers is related to increased loss of function. This seems unlikely from the data shown.

Insipite of our reservations, this is still an important study which highlights the potential of EMT to be central to COPD pathophysiology. Acceptance of this new concept will change the very way we think about this disease process and its nasty clinical consequences.

Abbreviations
BOS: Bronchiolitis obliterans syndrome; COPD: Chronic obstructive pulmonary disease; EMT: Epithelial mesenchymal transition; IF: Idiopathic pulmonary fibrosis; LP: Lamina propria; NK: Natural killer cells; Rbm: Reticular basement membrane; uPAR: Urokinase plasminogen activator receptor.

Competing interests
Authors declare that they do not have any competing interests.

Authors’ contributions
SSS: Literature search, figures, performed the histological analyses, data collection, data interpretation and writing. EHW: design of study, clinical assessments, overview of all analyses, data interpretation and writing. Both authors read and approved the final manuscript.

Received: 16 October 2013 Accepted: 5 November 2013
Published: 6 November 2013

References
1. Wang Q, Wang Y, Zhang Y, Xiao W: The role of uPAR in epithelial-mesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease. Respir Res 2013, 14:67.
2. Sohal SS, Walters EH: Epithelial mesenchymal transition (EMT) in small airways of COPD patients. Thorax 2013, 68(3):783–784.
3. Sohal SS, Ward C, Danial W, Wood-Baker R, Walters EH: Recent advances in understanding inflammation and remodeling in the airways in chronic obstructive pulmonary disease. Expert Rev Respir Med 2013, 7(3):275–288.
4. Sohal SS, Soltani A, Weston S, Wood-Baker R, Walters EH: Intermediate filament vimentin and potential role in epithelial mesenchymal transition (EMT). In Vimentin Concepts and Molecular Mechanisms. Editted by de Mello RA. New York: Nova Publishers; 2013:37–62.
5. Sohal SS, Reid D, Soltani A, Ward C, Weston S, Muller HK, Wood-Baker R, Walters EH: Reticular basement membrane fragmentation and potential epithelial mesenchymal transition is exaggerated in the airways of smokers with chronic obstructive pulmonary disease. Respiratory 2010, 15(6):930–938.
6. Sohal SS, Reid D, Soltani A, Ward C, Weston S, Muller HK, Wood-Baker R, Walters EH: Evaluation of epithelial mesenchymal transition in patients with chronic obstructive pulmonary disease. Respir Res 2011, 12(1):130.
7. Soltani A, Muller HK, Sohal SS, Reid DW, Weston S, Wood-Baker R, Walters EH: Distinctive characteristics of bronchial reticular basement membrane and vessel remodelling in chronic obstructive pulmonary disease (COPD) and in asthma: they are not the same disease. Histopathology 2012, 60(6):964–970.
8. Soltani A, Reid DW, Sohal SS, Wood-Baker R, Weston S, Muller HK, Walters EH: Basement membrane and vascular remodelling in smokers and chronic obstructive pulmonary disease: a cross-sectional study. Respir Res 2010, 11(1):105.
9. Soltani A, Sohal SS, Reid D, Weston S, Wood-Baker R, Walters EH: Vessel-associated transforming growth factor-beta1 (TGF-beta1) is increased in the bronchial reticular basement membrane in COPD and normal smokers. PLoS One 2012, 7(6):e39736.
10. Coward WR, Saini G, Jenkins G: The pathogenesis of idiopathic pulmonary fibrosis. Thor Adv Respir Dis 2010, 4(3):367–388.
11. Ward C, Forrest IA, Murphy DM, Johnson GE, Robertson H, Cawston TE, Fisher AJ, Dark JH, Lordan JL, Kirby JA, et al: Phenotype of airway epithelial cells suggests epithelial to mesenchymal cell transition in clinically stable lung transplant recipients. Thorax 2005, 60(10):865–871.
12. Kakuri R, Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 2005, 119(6):1420–1428.
13. Grigorou BD, Deportier F, Scherpereel A, Gourcero D, Devos P, Guastas T, Lafitte JJ, Copin MC, Tonnell AB, Lassalle P: Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 2006, 12(15):4575–4582.
14. Sarrazin SMC, Delmas D, Lassalle P, Delehedde M: Endocan as a biomarker of endothelial dysfunction in cancer. *J Cancer Sci Ther* 2010, 2(2):047–052.
15. Kalluri R, Zeisberg M: Fibroblasts in cancer. *Nat Rev Cancer* 2006, 6(5):392–401.
16. Garber K: Epithelial-to-mesenchymal transition is important to metastasis, but questions remain. *J Natl Cancer Inst* 2008, 100(4):232–233.
17. Barnes PJ, Adcock IM: Chronic obstructive pulmonary disease and lung cancer: a lethal association. *Am J Respir Crit Care Med* 2011, 184(8):866–867.
18. De Torres JP, Marin JM, Casanova C, Cote C, Carrioz S, Cordoba-Lanus E, Baz-Davila R, Zulueta JJ, Aguirre-Jaime A, Saetta M, et al: Lung cancer in patients with COPD: incidence and predicting factors. *Am J Respir Crit Care Med* 2011, 184(8):913–919.
19. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD: COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. *Eur Respir J* 2009, 34(2):380–386.

doi:10.1186/1465-9921-14-120

Cite this article as: Sohal and Walters: Role of epithelial mesenchymal transition (EMT) in chronic obstructive pulmonary disease (COPD). *Respiratory Research* 2013 14:120.